News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
News Alkermes closing in on Biogen with MS rival ALKS 8700 may have fewer side effects than Tecfidera.
News Biogen takes on Tecfidera adherence issues Company hopes to coach patients with stomach side-effects.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
